enGene Therapeutics (ENGN) vs Pelthos Therapeutics (PTHS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Pelthos Therapeutics (PTHS) has outperformed enGene Therapeutics (ENGN) over the past year, losing 24.5% versus a loss of 76.0%. enGene Therapeutics is the larger company by market cap ($116.9 million vs $80.8 million), about 1.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ENGN | PTHS |
|---|---|---|
| Share price | $1.75 | $21.10 |
| Market cap | $116.94M | $80.78M |
| 1-day change | -1.97% | +2.93% |
| YTD return | -80.29% | -33.87% |
| 1-year return | -75.98% | -24.47% |
| EPS (TTM) | $-2.07 | $-27.53 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $12.25 | $37.50 |
| 52-week low | $1.40 | $18.19 |
| Distance from 52-week high | -85.76% | -43.73% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +88.54% | +151.85% |
| Average volume | 748.14K | 60.07K |
| Shares outstanding | 67.02M | 3.83M |
| Employees | 81 | 92 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PTHS has outperformed ENGN by 51.5 percentage points over the past year.
About enGene Therapeutics
ENGN stock →enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 81 employees
About Pelthos Therapeutics
PTHS stock →Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older; XEPI, (ozenoxacin) cream, a quinolone antimicrobial for the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients 2 months of age and older; and XEGLYZE, a pediculicide indicated for topical treatment of head lice infestation in patients 6 months of age and older.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 92 employees
ENGN vs PTHS FAQ
Which is bigger, enGene Therapeutics or Pelthos Therapeutics?
enGene Therapeutics (ENGN) is larger, with a market capitalization of $116.94M compared with $80.78M for Pelthos Therapeutics (PTHS).
Which stock has performed better over the past year, ENGN or PTHS?
PTHS returned -24.47% over the past 12 months, compared with -75.98% for ENGN (price return, excluding dividends). Past performance does not predict future results.
Are enGene Therapeutics and Pelthos Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.